Copyright © 2019 EnBiotix, Inc.. All Rights Reserved

A Critical Unmet Need in Cystic Fibrosis (CF):

CF Patients Worldwide
% Receive Tobramycin
Tobramycin Cost/Yr ($)
Median CF Survival (yrs)

Chronic, Recurrent Lung Infections Associated with Early Mortality:

  • >80% of CF deaths attributable to progressive lung disease
  • Most CF patients develop chronic Pseudomonas infections at an early age
  • Inhaled tobramycin is a cornerstone of CF therapy
  • Current antibiotic treatment fails to eradicate due to bacterial persisters

EBX-001 is a combination of tobramycin (TOB) with fumarate (as an antibacterial potentiator) for the eradication of  P. aeruginosa (Pae) persisters.  EBX-001 significantly enhances killing of Pae persisters through a novel proton-motive-force (PMF) enhancing mechanism.  EBX-001 data show up to 6 orders-of-magnitude enhanced killing of Pae persisters over a range of CF isolates, including mucoid and non-mucoid strains, compared to TOBI alone, as well as complete eradication of Pae biofilms.  EBX-001 is initially being developed for treatment of Pae infections in CF patients, although market expansion to non-CF bronchiectasis (nCFBE) and COPD is envisioned.

Dose-dependent fumarate potentiation on TOB sensitivity in Pae non-mucoid & mucoid CF isolates

 Eradication of Pseudomonas mucoid and non-mucoid CF isolate colony biofilms  

Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O’Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D. 2017. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother 61:e00987-17.